The median rwToT with first-line pembrolizumab monotherapy was 7.6 months (95% CI, 6.3–10.6) for patients with KRAS-mutated NSCLC, 7.0 months (95% CI, 5.3–9.3) for those with KRAS wild-type tumors, and 7.6 months (95% CI, 6.3–8.8) for all patients with nonsquamous tumors (Table 3, Figure 3). Here, KRAS is linked to non-small cell lung carcinoma.